The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Subscribe To Our Newsletter & Stay Updated
